Background: In the reconstruction of burns using split-skin grafts (SSGs), fibrin glue can be used to improve graft take and reduce haematoma formation, although the efficacy and cost-effectiveness are unknown. This systematic review evaluated outcomes of fibrin glue compared with conventional SSG attachment techniques. Outcomes of interest included SSG take, haematoma formation, patient satisfaction and cost-effectiveness.
Introduction
Burn injuries are common, and continue to pose a complex and expensive challenge for healthcare providers globally 1 -3 . The surgical management of burns aims to facilitate timely wound healing, ideally within 2 weeks, to maximize function of the affected area and minimize pathological scarring 4 . Once the burned skin has been debrided (using a blade, hydrosurgery 5, 6 or enzymatic debridement 7 ) there may be insufficient healthy dermis remaining to achieve spontaneous wound healing within an appropriate timescale. In this situation, an autologous split-skin graft (SSG) may be used to reconstruct the wound bed. The SSG is harvested from an area of unburned skin, the thickness can be selected, and it is then either left as a sheet or meshed before being inset to the burn wound bed. Attaching the skin graft to the wound bed facilitates graft take, with particular emphasis on minimizing shear forces 8 . Skin grafts that do not adhere will undergo necrosis, necessitating either revision or healing by secondary intention, with additional morbidity and cost. In burns involving a large proportion of the body, measured by the percentage total body surface area (TBSA), it may be challenging to find sufficient non-burned skin to harvest, emphasizing the goal of achieving a successful skin graft at the first attempt.
Conventionally, skin grafts are secured with either sutures, staples, tissue glue, dressings (tie-on, tie-over or negative pressure) or a combination of these techniques. Fibrin glue or sealants were first introduced as haemostatic agents in 1909 and later in skin grafts during the Second World War 9 . They contain two key substances: fibrinogen and thrombin; these can be either autologous or synthetic 10 . The solution can be modified with additives such as growth factors, other blood products (for example, platelets) or medications (such as antibiotics) 11 . Since approval by the Food and Drug Administration (FDA) in 1998 12 , there have been significant advances in their application; there are now four FDA-approved fibrin sealants available for topical use 13 . Fibrin glue has been used across surgical specialties, with several delivery systems available 13, 14 .
Fibrin glue has been described widely for skin grafting, most extensively for SSG attachment following burn surgery 15 -21 . Studies suggest a number of benefits, including improved graft take, reduced haematoma formation 18 , improved donor-site haemostasis 22 and improved functional outcomes 23 . However, fibrin glues are expensive and there is no clear evidence of their superiority over other techniques for securing SSGs. The aim of this review was to evaluate systematically the literature that compares fibrin glue with conventional methods of skin graft attachment in patients with burn wounds.
Methods
This systematic review was performed in accordance with PRISMA guidelines 24 and the Cochrane Handbook for Systematic Reviews of Interventions 25 . The protocol was developed prospectively, peer-reviewed and registered in the PROSPERO database (CRD42017082677) 26 .
Search strategy
The Cochrane Library, Embase, PubMed, ClinicalTrials .gov and PROSPERO databases were searched from inception until January 2018 (Appendix S1, supporting information). Only human studies were considered. Authors of trials registered in ClinicalTrials.gov were contacted if data had not been published. Titles and abstracts were screened independently by two authors. Full texts of potentially relevant articles were retrieved for consideration of inclusion. Reference lists of the included papers and previous reviews were screened for additional papers. Disagreements were resolved by a third author.
Study selection
Included study types were randomized or quasirandomized trials, observational studies, systematic reviews and meta-analyses. Case reports were excluded. There was no restriction on patient age. Studies were included if they compared fibrin glue directly with conventional methods of SSG attachment in burn wounds. Studies using within-participant randomization or variations were included. Studies were included if they reported one or more of the following outcomes: skin graft take, skin graft loss, postoperative infection, postoperative pain, return to the operating theatre, patient satisfaction, postoperative haematoma, postoperative wound breakdown and scar outcome.
Data extraction
Data were extracted on to a predefined electronic data extraction form by one author, and checked separately by another author. The published data from included studies were scrutinized for reporting of outcomes. If relevant data were not available for extraction, the corresponding author was contacted by e-mail with a specific data request. If there was no reply, a reminder e-mail was sent after a week. If again no response was received, a further e-mail was sent. If there was still no response, the study was excluded and the authors notified.
Outcomes
The primary outcome was skin graft take. Secondary outcomes included overall wound closure, graft loss, haematoma formation, pain, patient satisfaction, blood loss, cost-effectiveness, return to theatre and postoperative infection.
Risk-of-bias assessment
The risk of bias for RCTs was assessed using the Cochrane risk-of-bias tool. The risk of bias for non-randomized studies was evaluated using the Risk Of Bias In Non-Randomized Studies -of Intervention (ROBINS-I) tool 27 . The risk-of-bias judgements were summarized across studies for each of the domains listed. When considering treatment effects, bias assessment was done at an outcome level. A descriptive assessment of risk affecting the cumulative evidence was conducted using the GRADE tool 28 to establish the quality of evidence and the strength of recommendations.
Data analysis
A descriptive analysis was performed for all outcomes to allow narrative evaluation of difference in outcomes. Data were insufficient for any pooled analysis or an assessment of publication bias.
Results

Study selection
In total, 168 articles were identified. Ultimately, six full-text articles 15, [18] [19] [20] [21] 29 were included. Articles were excluded based on the population (fibrin glue used for skin grafting in non-burned patients or used exclusively on donor sites), the intervention (keratinocyte application rather than fibrin glue) and lack of comparison groups ( Fig. 1) . 20, 21, 29 . Medical co-morbidities were not reported in four studies 18, 19, 21, 29 .
Study characteristics
One study 15 documented no co-morbidities, and another 20 reported smoking and diabetes only, with no significant difference between groups. Half of the included studies received funding from Baxter Healthcare. Two studies 30, 31 were not in the English language and full texts could not be retrieved for translation, resulting in their exclusion.
Study results
Overall, graft take and graft loss were similar in the fibrin glue and control groups ( Table 2) . No adverse events attributed to fibrin glue were reported in any study. There was insufficient information to report on return to the operating theatre or postoperative infection. Formal direct comparison by meta-analysis was not possible owing to issues of unit of analysis and variable outcome reporting. Three studies reported graft take at 5 days; one 19 was a within-participant intervention study with the unit of analysis being the site, whereas the other two studies 15, 18 randomized individual patients to interventions with the unit of analysis being the patient. Only two studies 18, 19 reported long-term graft take and haematoma formation. 
Graft take
Graft take was assessed most commonly on day 5 (183 individuals) 15, 18, 19 . Boccara and colleagues 15 reported that all grafts took without lysis or necrosis. Ihara and co-workers 21 found no difference in graft take between groups, although no supporting statistics were given. The rate of graft take reported by Foster et al. 18 was 62⋅3 per cent for fibrin glue and 55⋅1 per cent for control (P = 0⋅089). The rate of graft take documented by Gibran and colleagues 19 was 62 and 46 per cent for fibrin glue and control respectively (P = 0⋅07).
Wound closure
Overall wound healing was described by proportions healed on day 14 18, 19 and at 1 month 20 ; time to complete healing was reported in two studies 15, 29 . One study 21 did not report this outcome. There was no difference in complete wound healing on day 14 between groups (48⋅8 versus 42⋅6 per cent for fibrin glue versus control; P = 0⋅230) 18 or the decrease in wound size (18⋅3 versus 14⋅7 per cent respectively; P = 0⋅773) 19 . Gibran and co-workers 19 reported 100 per cent graft survival in both groups on day 14 (P = 0⋅352). Although mentioned in the methods, Butts et al. 20 did not report rates of complete wound closure. Boccara and colleagues 15 reported complete wound closure after a mean of 17 days, but with no comparison between the six patients with treatment and control burn sites. McGill and co-workers 29 reported no significant difference between groups in wound healing time after adjustment for graft size (mean(s.d.) 5(4) versus 18(64) days per 100 cm 2 ; P = 0⋅77). One study 18 reported odds ratios for complete wound closure on day 28 after treatment for the fibrin glue group according to the surgical site, rather than comparing with staples.
Graft loss
Three studies considered graft loss 18 -20 . Butts et al. 20 reported significantly lower graft loss rates in the fibrin glue group (less than 1 per cent versus 4 per cent for control; P = 0⋅03). Foster and co-workers 18 noted partial or complete graft loss as the most common adverse event in both treatment and control groups (25⋅4 and 23⋅2 per cent respectively), but without statistical comparison. Gibran and co-workers 19 reported 48 episodes of graft loss over the study (18 
Haematoma formation
Haematoma formation was assessed in three studies 15, 18, 19 . This was most commonly evaluated on day 1. Foster and colleagues 18 reported a significant reduction in the rate of haematoma in fibrin glue-treated sites compared with control (29⋅7 versus 62⋅3 per cent; P < 0⋅001). Gibran et al. 19 reported a significantly lower median percentage grafted area with haematoma (0⋅0 versus 2⋅1 per cent; P = 0⋅014). Boccara and co-workers 15 commented that seroma or serosanguinous collection was more common with fibrin glue but provided no supporting statistics. Butts et al. 20 stated that they measured haematoma rates in their methods, but did not report these results.
Pain
Pain was reported by two studies 15, 18 . Using a visual analogue scale (VAS), Boccara et al. 15 reported that pain scores were lower with fibrin glue than staples (mean 1⋅66 (range 0-4) versus 4⋅33 (range 3-6); P = 0⋅004) in the six patients in whom comparison was possible. Foster and co-workers 18 reported significantly higher mean pain scores after staple removal compared with before removal (6 versus 3; P < 0⋅001), indicating that staples were more painful. However, they offered no pain score data for the fibrin glue test sites. Overall, patients reported less anxiety about pain with fibrin glue compared with staples.
Patient satisfaction
Patient satisfaction was reported by one study 18 using within-subject controls. A significant preference for fibrin glue over staples was noted on days 5, 14 and 28, and at 12 months (P < 0⋅001), although the raw data were not available.
Blood loss
Two 21,29 studies focused on blood loss and the use of blood products, rather than graft take or healing. Ihara and colleagues 21 reported a blood transfusion requirement of 1226 ml in the fibrin glue group compared with 2038 ml in the control group. Their observations regarding improved haemostasis with fibrin glue were subjective. McGill et al. 29 reported no statistically significant difference in estimated blood loss or decrease in haemoglobin level between the fibrin glue and non-fibrin glue groups. In subgroup analyses, they demonstrated a significant reduction in estimated blood loss for subjects aged at least 16 years (0⋅5 versus 0⋅8 ml per cm 2 graft size; P = 0⋅03), and a significant reduction after adjustment for graft size in one of the two centres. They also reported significantly less requirement for red blood cells (P = 0⋅02) and 5 per cent albumin (P = 0⋅001) in the fibrin glue groups, although these data were complete for only one centre.
Cost-effectiveness
Cost savings were addressed in in four studies 15, 18, 20, 29 .
McGill and colleagues 29 suggested that fibrin glue resulted in cost savings of up to US $1500 (€1313, exchange rate 27 October 2018) per patient as a result of lower transfusion requirements. Boccara et al. 15 suggested cost savings through reduced analgesia, and medical and paramedical staff input, but provided no objective data to support this statement. Foster and co-workers 18 made similar comments, but again without objective data. The only study to assess cost objectively was that of Butts and colleagues 20 , who reported a mean decrease in duration of hospital stay of 1⋅8 days in the fibrin glue group and suggested a saving of US $746 (€652) per patient; however, this was not statistically significant. Duration of stay was discussed further in two studies 15, 29 . Boccara et al. 15 commented that all patients treated with fibrin glue were typically discharged on the third postoperative day, whereas patients treated without fibrin glue were typically discharged on the fifth day; however, no statistics were reported so no inferences can be made. The second study 29 reported a significant reduction in duration of stay with use of fibrin glue compared with that in control patients, but not when adjusted for graft size (3(4) versus 5(7) days; P = 0⋅26).
Risk of bias within studies
All studies were considered at risk of methodological bias ( Fig. S1 and Table S1 , supporting information). The risk of bias is given at the outcome level for each study, except that of Boccara et al. 15 .
Risk of bias across studies
There was a significant risk of bias across the studies regarding the use of control groups. Of the six included studies, only two were RCTs 18, 19 . Both used within-subject controls and neither the subject nor assessor was blinded to outcome measurement, except in the study by Foster and colleagues 18 where assessors were blinded to complete wound closure on day 28. Neither study gave details of patient recruitment or randomization sequence generation, and there was poor reporting of intention-to-treat (ITT) analysis and information regarding missing data. Foster et al. 18 excluded from their ITT analysis participants with no primary outcome data, those lost to follow-up and those without photographs on day 28. This was reported within FDA product development information 13 , but not in the published study. However, further details regarding differences between treatment groups were not given, introducing the risk of bias.
Of the four cohort studies, one 15 used within-subject controls, but for only six patients. For these patients it was not reported whether the two burn sites were comparable or how they were chosen. The remaining three studies used retrospective controls. Ihara et al. 21 did not clearly define their control group, nor was it comparable in terms of percentage TBSA and there was no assessment of differences in patient or burn characteristics between groups. Butts and colleagues 20 presented a comparison of patient and burn characteristics between cases and controls. However, the controls were from 2007-2008 and the cases from 2011-2012, which may have led to a systematic difference between groups in patient management. McGill and co-workers 29 used mixed methods; they identified patients for fibrin glue prospectively (they were recruited for a different study concerning the manufacture of fibrin glue to prevent viral contamination), whereas controls were identified retrospectively and comprised patients who declined participation in the parent study. Insufficient information was provided regarding the management of control patients, who were recruited across two institutions, which increased the risk of bias.
The composition of fibrin glue is a further potential source of bias across studies. Although this should not introduce a systematic error, there may be an error over time. Recent studies use a more consistent and refined fibrin glue. Ihara and colleagues 21 in 1984 and McGill et al. 29 in 1997 described a process of fibrin glue synthesis from fibrinogen solution and thrombin solution immediately before intraoperative application. Ihara and colleagues 21 used a thrombin concentration of 4⋅2 units/ml. The method of application was not described, although the solutions were mixed before application. In contrast,
McGill and co-workers 29 18 reported clinical trials for the development of the same product (ARTISS; Baxter Healthcare, Sydney, New South Wales, Australia). Both used 4 units/ml thrombin with the sealant, although the fibrin glue was heat-and solvent-treated in the study by Foster et al. 18 , but not in that by Gibran et al. 19 . Both components were administered by spray. Butts and colleagues 20 and Boccara et al. 15 used ARTISS in 2015 and 2017 respectively.
Quality of evidence and strength of recommendations
The overall quality of the research concerning fibrin glue was very low and so it is not possible to make recommendations regarding its use (Table S2 , supporting information).
Discussion
Fibrin glue is used widely across surgical subspecialties. There have been many recent advances in its synthesis and application. However, despite over half a century of use in burns, there is little evidence to support the use of fibrin glue in this patient group. The search identified only 18 full-text articles for review. Nine of these provided no comparison group and were therefore excluded; only six studies qualified for inclusion. Both RCTs 18, 19 were funded by Baxter Healthcare which produces ARTISS, and both were at high risk of bias. Both excluded hands and genital burns, chemical burns and diabetics, which limits extrapolation of the results to all burn surgery. However, these exclusion criteria are reasonable to facilitate a comparative study. Furthermore, blinding of participants and investigators for the majority of outcomes was not possible, although Foster and colleagues 18 did use blinded investigators for the primary endpoint analysis on day 28 using photographs, finding that fibrin glue was at least as effective as staples. Regarding the non-randomized studies, levels of bias were critical in two, serious in one and high in one. Taken together, the overall level of evidence for the use of fibrin glue in burn surgery is poor.
The results suggest that there is insufficient evidence to support the use of fibrin glue in terms of improved skin graft take or wound closure. No meaningful difference was demonstrated for these outcomes in any study, although one 20 suggested that fibrin glue may reduce graft loss, reporting a significantly lower graft loss rate in the fibrin glue group. However, it is not clear what statistical analysis was conducted and, given the low numbers involved, provides only weak evidence. Furthermore, the heterogeneity of terms used to describe the clinical assessment of grafts, particularly on day 5, makes interpretation of outcomes challenging. Terms used included engraftment 18 , surgical closure (defined as graft vascularization and formation of a contiguous layer of viable epithelium covering the entire wound) 19 , percentage area of questionable viability 19 , graft take 15 and graft fixation 21 . Although these terms give an assessment of skin graft success at the time of review, and therefore facilitate comparison between treatment groups, they are probably not synonymous across studies. Clear and practical definitions are required for future studies that will facilitate comparison, and clear outcomes need to be stated, such as graft adherence or graft take.
Fibrin glue appeared to reduce postoperative haematoma formation 15, 19 . Both RCTs demonstrated a significant reduction in haematoma formation 24 h after surgery. However, the third study 15 comments that rates of seroma or serosanguinous collection were more common with fibrin glue, but no statistics were provided to qualify their claim. The authors attributed this observation to fibrin glue obstructing fenestrations made in the SSGs.
The two studies 21, 29 that focused primarily on blood loss did not measure haematoma formation. Ihara and colleagues 21 reported reduced blood loss, with a lower requirement for blood products in the fibrin glue group; however, they did not control for differences in percentage TBSA (47⋅5 and 56⋅0 per cent in fibrin glue and control groups respectively), which may have confounded the outcome. McGill et al. 29 found no significant difference in blood loss overall when adjusted for graft size, although it was significantly reduced in one of their centres. In a subgroup analysis, patients aged 16 years or over showed significantly less blood loss; however, the data were generated from estimates made by the surgical and anaesthetic teams based on the amount of blood collected on swabs and in the suction catheters. Furthermore, these data were collected retrospectively from charts.
Data regarding red blood cell transfusion volume were available from only one centre, and the median volume administered to the treatment and control groups was 0 ml 29 . Of note, articles assessing blood loss were from 1984 21 and 1997 29 so it is reasonable to suggest that operative techniques may have evolved, with more widespread use of subcutaneous infiltration of adrenaline solutions, improvements in excisional surgery techniques and the advent of hydrosurgical debridement. A further point for consideration in relation to graft take and haemostasis is the thickness of fibrin glue; this was reported in the methods of only two papers 18, 19 during the development of ARTISS, which had a recommended dose of 2-4 ml per 100 cm 2 . No articles reported the dose used or thickness applied. A thicker layer of fibrin glue might provide better haemostasis and adherence, but it could also impede revascularization or increase haematoma rates owing to obstruction of fenestrations.
Fibrin glue may be beneficial for reducing pain 15, 18 and duration of hospital stay 15, 20, 29 , with subsequent improvements in patient satisfaction 18 and costs. It is logical that there will be less pain if staples are not removed; this was supported by two studies 15, 18 . The costs of fibrin glue will necessarily increase overall costs, but savings may be made from reductions in inpatient stay 20 . A detailed economic analysis of the use of fibrin glue in burn wound reconstruction should be incorporated into future RCTs.
The role of fibrin glue in elective surgery was assessed recently in a systematic review and meta-analysis 14 . This excluded all studies included in the present review as burn injuries did not meet the inclusion criteria. Meta-analysis of 32 included RCTs demonstrated no difference in the risk of seroma with fibrin glue (odds ratio (OR) 0⋅84, 95 per cent c.i. 0⋅68 to 1⋅04; P = 0⋅13; n = 3472; I 2 = 12⋅7 per cent), but a significant benefit regarding haematoma formation from 24 studies (OR 0⋅62, 0⋅44 to 0⋅86; P = 0⋅01; n = 2403; I 2 = 0 per cent). This is in keeping with the present findings.
In the plastic surgery literature, fibrin glue has been used for haemostasis at skin grafting donor sites in two RCTs 32, 33 , one of which reported a small beneficial effect and the other no effect. In the burns literature, several groups have reported improved wound healing 16,34 -36 , graft adherence 16,34 -38 , reduced blood loss 39 and improved haemostasis 16, 34, 37 with fibrin glue. Additional advantages may include the use of fibrin glue for skin graft attachment in areas that are hard to graft such as the face, eyelids and ears, and areas of high mobility 35, 37 , use in diabetics and smokers 38 , and improved functional outcomes with fibrin glue use 40 . Unfortunately, the majority of these studies were of poor quality and at high risk of bias. They were excluded from this review as they provided no comparison groups or were conducted in mixed patient groups (such as skin grafting for trauma and chronic wounds), not specifically burn surgery.
The safety of fibrin glue is an important consideration. None of the included studies reported adverse outcomes attributed to fibrin glue. There have been concerns regarding viral transmission with the use of synthetic fibrin glue, which is overcome by use of autologous fibrin glue; however, the general consensus is that fibrin glue is risk-free 32 . A significant safety concern was raised regarding air embolism with fibrin glue spray delivery systems. However, the European Medical Agency concluded that the benefits outweighed the risks 14, 41 . Furthermore, this complication was seen predominantly in intra-abdominal or vascular surgery and is unlikely to arise in skin grafting.
This study had a number of limitations. At an outcome level, it was limited by the level of bias demonstrated across the included studies and reflected by the very low GRADE score (Table S2 , supporting information). No studies reported risk or odds ratios, and the definitions used for graft take, graft adherence and wound healing were inconsistent. A significant challenge, as in many surgical studies, is achieving adequate control groups, and blinding. The use of within-subject controls in the two RCTs offers significant advantages, but limits the size and type of burn injuries that can be included. Furthermore, given the type of interventions being assessed, blinding is a significant challenge until after staples have been removed. For the remaining studies, matching of cases and controls was weak throughout. On a study level, this review was limited by the risk of publication bias. Researchers are unlikely to report poor outcomes from the use of fibrin glue, particularly when funded by a pharmaceutical company.
The quality of evidence for the use of fibrin glue in skin grafting for burn injuries is very low and based on few studies with significant risks of methodological bias. No meaningful conclusions can be drawn, and no recommendations suggested. The inconsistency in outcome reporting encountered here supports the need for agreement regarding the core outcomes, and how they should be measured and reported in future studies.
